CLAIMS

1. Use of a first population of allogeneic T cells that bind or recognize a first epitope of an EBV antigen in the manufacture of a medicament for the treatment or prevention of an EBV-associated disease, disorder or condition in a subject; wherein the first population of allogeneic T cells is to be administered in combination with a therapeutic agent, wherein the therapeutic agent is selected from the group consisting of an immunotherapeutic agent, a MAPK pathway inhibitor, a BET inhibitor and any combination thereof; and optionally a second population of allogeneic T cells that bind or recognize a second epitope of the EBV antigen or a further EBV antigen.

~~1. A method of treating or preventing an EBV-associated disease, disorder or condition in a subject, said method including the steps of:~~

~~(a) administering to the subject a first population of allogeneic T cells that bind or recognize a first epitope of an EBV antigen; and~~

~~(b) administering to the subject a second population of allogeneic T cells that bind or recognize a second epitope of the EBV antigen or a further EBV antigen;~~

~~to thereby treat or prevent the EBV-associated disease, disorder or condition in the subject.~~

2. A pharmaceutical composition for treating or preventing an EBV-associated disease, disorder or condition in a subject, the composition comprising:
   (a) a first population of allogeneic T cells that bind or recognize a first epitope of an EBV antigen; and/or
   (b) a therapeutic agent, wherein the therapeutic agent is selected from the group consisting of an immunotherapeutic agent, a MAPK pathway inhibitor, a BET inhibitor (e.g JQ1) and any combination thereof; and
   (c) a pharmaceutically acceptable carrier, diluent and/or excipient; and optionally
   ~~(b)~~(d) a second population of allogeneic T cells that bind or recognize a second epitope of the EBV antigen or a further EBV antigen.~~; and~~
   ~~(c) optionally a pharmaceutically acceptable carrier, diluent and/or excipient.~~

3. The ~~method~~ use of c~~C~~laim 1 or the composition of ~~C~~claim 2, wherein the first population of allogeneic T cells and cells of the EBV-associated disease, disorder or condition both

comprise or are restricted by a first human leukocyte antigen (HLA) allele that encodes a first MHC protein.

4. The ~~method~~ use or composition of c~~C~~laim 3, wherein the first MHC protein presents the first epitope of the EBV antigen on cells of the EBV-associated disease, disorder or condition.

5. The ~~method~~ use or composition of any one of c~~C~~laims 1 to 4, wherein the second population of allogeneic T cells and cells of the EBV-associated disease, disorder or condition both comprise or are restricted by a second HLA allele that encodes a second MHC protein, wherein the second MHC protein presents the second epitope of the EBV antigen or the further EBV antigen on cells of the EBV-associated disease, disorder or condition.

~~6. The method or composition of Claim 5, wherein the second MHC protein presents the second epitope of the EBV antigen or the further EBV antigen on cells of the EBV-associated disease, disorder or condition.~~

~~7.~~6. The ~~method~~ use of any one of c~~C~~laims 1 and 3 to ~~6~~5, wherein the second population of allogeneic T cells is administered prior to, simultaneously with and/or subsequent to administration of the first population of allogeneic T cells.

~~8.~~7. The ~~method~~ use of any one of c~~C~~laims 1 and 3 to ~~7~~6, further including the initial step of generating the first and/or second populations of allogeneic T cells *in vitro*.

~~9. The method of any one of Claims 1 and 3 to 8, including the further step of administering a therapeutic agent to the subject.~~

~~10. The method of Claim 9, wherein the therapeutic agent is selected from the group consisting of an immunotherapeutic agent, a MAPK pathway inhibitor, a BET inhibitor and any combination thereof.~~

~~11.~~8. The use or composition of any one of the preceding claims, ~~A pharmaceutical combination, comprising the pharmaceutical composition of Claim 2, together with an immunotherapeutic agent, a MAPK pathway inhibitor, a BET inhibitor, or a combination~~

~~thereof~~wherein the MAPK pathway inhibitor is or comprises a MEK1/2 inhibitor selected from selumetanib and/or trematinib.

~~12. A method of treating or preventing an EBV-associated disease, disorder or condition in a subject, said method including the steps of:~~

~~(a) administering to the subject a population of allogeneic T cells that bind or recognize an epitope of an EBV antigen; and~~

~~(b) administering to the subject a therapeutic agent, wherein the therapeutic agent is selected from the group consisting of an immunotherapeutic agent, a MAPK pathway inhibitor, a BET inhibitor and any combination thereof;~~

~~to thereby treat or prevent the EBV-associated disease, disorder or condition in the subject.~~

~~13. A pharmaceutical composition for treating or preventing an EBV-associated disease, disorder or condition in a subject, the composition comprising:~~

~~(a) a population of allogeneic T cells that bind or recognize an epitope of an EBV antigen;~~

~~(b) a therapeutic agent, wherein the therapeutic agent is selected from the group consisting of an immunotherapeutic agent, a MAPK pathway inhibitor, a BET inhibitor and any combination thereof; and~~

~~(c) optionally a pharmaceutically acceptable carrier, diluent and/or excipient.~~

~~14.~~9. The ~~method~~ use of c~~C~~laim ~~12~~ 1 or the composition of c~~C~~laim ~~13~~2, wherein the population of allogeneic T cells and cells of the EBV-associated disease, disorder or condition both comprise or are restricted by a human leukocyte antigen (HLA) allele that encodes a MHC protein, wherein the MHC protein presents the epitope of the EBV antigen on cells of the EBV-associated disease, disorder or condition, wherein the EBV antigen and/or the further EBV antigen is selected from the group consisting of EBNA1, EBNA2, EBNA3A, EBNA3B, EBNA3C, LMP1, LMP2 and any combination thereof.

~~15. The method or composition of Claim 14, wherein the MHC protein presents the epitope of the EBV antigen on cells of the EBV-associated disease, disorder or condition.~~

~~16.~~10. The ~~method~~use ~~, combination,~~ or composition of any one of ~~Claims 10 to 15~~the preceding claims, wherein the immunotherapeutic agent is or comprises an immune checkpoint inhibitor, such as a PD1 inhibitor (e.g., an anti-PD1 antibody selected from

Pembrolizumab, Nivolumab, or Cemiplimab), a PD-L1 inhibitor (e.g., an anti-PD-L1 antibody selected from Atezolizumab, Avelumab, or Durvalumab), a CTLA4 inhibitor (e.g., an anti-CTLA4 antibody), a LAG3 inhibitor (e.g., an anti-LAG3 antibody), a TIM3 inhibitor (e.g., an anti-TIM3 antibody), or a CD96 inhibitor (e.g., an anti-CD96 antibody).

~~17. The method or composition of Claim 15, wherein the immune checkpoint inhibitor is or comprises an anti-PD1 antibody.~~

~~18. The method or composition of Claim 16, wherein the anti-PD1 antibody is selected from Pembrolizumab, Nivolumab, or Cemiplimab.~~

~~19. The method or composition of Claim 15, wherein the immune checkpoint inhibitor is or comprises an anti-PD-L1 antibody.~~

~~20. The method or composition of Claim 19, wherein the anti-PD1 antibody is selected from Atezolizumab, Avelumab, or Durvalumab.~~

~~21. The method, combination, or composition of any one of Claims 10 to 16, wherein the MAPK pathway inhibitor is or comprises a MEK1/2 inhibitor.~~

~~22. The method or composition of claim 21, wherein the MEK1/2 inhibitor is selected from selumetanib and/or trematinib.~~

~~23. The method, combination, or composition of any one of Claims 10 to 16, wherein the BET inhibitor is JQ1.~~

~~24.~~11. The ~~method~~ use of any one of ~~C~~claims ~~12~~ 1, ~~and 14~~ 3 to ~~23~~9, wherein the population of allogeneic T cells is administered prior to, simultaneously with and/or subsequent to administration of the therapeutic agent, optionally further including the initial step of generating the population of allogeneic T cells *in vitro*.

~~25. The method of any one of Claims 12 and 14 to 24, further including the initial step of generating the population of allogeneic T cells *in vitro*.~~

~~26. The method or composition of any one of the preceding claims, wherein the EBV antigen and/or the further EBV antigen is selected from the group consisting of EBNA1, EBNA2, EBNA3A, EBNA3B, EBNA3C, LMP1, LMP2 and any combination thereof.~~

~~27. The method or composition of Claim 26, wherein the EBV antigen and/or the further EBV antigen is or comprises EBNA1, LMP1 and/or LMP2.~~

~~28.~~12. The ~~method~~ use or composition of any one of the preceding claims, wherein the EBV-associated disease, disorder or condition is or comprises an EBV-associated cancer, wherein the EBV-associated cancer is selected from the group consisting of nasopharyngeal carcinoma, NKT cell lymphoma, Hodgkin's Lymphoma, post-transplant lymphoproliferative disease, Burkitt's lymphoma, Diffuse large B-cell lymphoma, gastric cancer, and any combination thereof.

~~29. The method or composition of Claim 22, wherein the EBV-associated cancer is selected from the group consisting of nasopharyngeal carcinoma, NKT cell lymphoma, Hodgkin's Lymphoma, post-transplant lymphoproliferative disease, Burkitt's lymphoma, Diffuse large B-cell lymphoma, gastric cancer, and any combination thereof.~~

~~30. Use of a first population of allogeneic T cells that bind or recognize a first epitope of an EBV antigen in the manufacture of a medicament for the treatment or prevention of an EBV-associated disease, disorder or condition in a subject; wherein the first population of allogeneic T cells is to be administered in combination with: (a) a second population of allogeneic T cells that bind or recognize a second epitope of the EBV antigen or a further EBV antigen; and/or (b) a therapeutic agent, wherein the therapeutic agent is selected from the group consisting of an immunotherapeutic agent, a MAPK pathway inhibitor, a BET inhibitor and any combination thereof.~~

13. A first population of allogeneic T cells that bind or recognize a first epitope of an EBV antigen for use in the treatment or prevention of an EBV-associated disease, disorder or condition in a subject; wherein the first population of allogeneic T cells is to be administered in combination with: (a) a second population of allogeneic T cells that bind or recognize a second epitope of the EBV antigen or a further EBV antigen; and/or (b) a therapeutic agent, wherein the therapeutic agent is selected from the group consisting of an

immunotherapeutic agent, a MAPK pathway inhibitor, a BET inhibitor (e.g., JQ1) and any combination thereof.

~~31.~~

~~32. A method~~The use of a population of allogeneic T cells that bind or recognize an epitope of an EBV antigen in the manufacture of a medicament for the treatment or prevention of ~~treating or preventing~~ an EBV-associated cancer or tumour in a subject~~;, said method including the steps of:~~

~~(a)~~ wherein the population of allogeneic T cells is to be administered in combination with ~~administering to the subject a population of allogeneic T cells that bind or recognize an epitope of an EBV antigen; and~~

~~(b) administering to the subject~~ a therapeutic agent, wherein the therapeutic agent is selected from the group consisting of an immunotherapeutic agent, a MAPK pathway inhibitor, a BET inhibitor and any combination thereof~~;~~

14. ~~to thereby treat or prevent the EBV-associated disease, disorder or condition in the subject~~.

~~33.~~15. A pharmaceutical composition for treating or preventing an EBV-associated cancer or tumour in a subject, the composition comprising:

(a) a population of allogeneic T cells that bind or recognize an epitope of an EBV antigen;

(b) a therapeutic agent, wherein the therapeutic agent is selected from the group consisting of an immunotherapeutic agent, a MAPK pathway inhibitor, a BET inhibitor and any combination thereof; and

(c) ~~optionally~~ a pharmaceutically acceptable carrier, diluent and/or excipient.

~~34.~~16. The ~~method~~ use of c~~C~~laim 14~~26~~ or the composition of c~~C~~laim 15~~27~~, wherein the population of allogeneic T cells and cells of the EBV-associated disease, disorder or condition both comprise or are restricted by a human leukocyte antigen (HLA) allele that encodes a MHC protein, wherein the MHC protein presents the epitope of the EBV antigen on cancer or tumour cells, wherein the EBV antigen and/or the further EBV antigen is selected from the group consisting of EBNA1, EBNA2, EBNA3A, EBNA3B, EBNA3C, LMP1, LMP2 and any combination thereof.

~~35. The method or composition of Claim 28, wherein the MHC protein presents the epitope of the EBV antigen on cancer or tumour cells.~~

~~36.~~17. The ~~method, combination,~~use or composition of any one of c~~C~~laims 14-16~~26 to 29~~, wherein the immunotherapeutic agent is or comprises an immune checkpoint inhibitor,

such as a PD1 inhibitor (e.g., an anti-PD1 antibody selected from Pembrolizumab, Nivolumab, or Cemiplimab), a PD-L1 inhibitor (e.g., an anti-PD-L1 antibody selected from Atezolizumab, Avelumab, or Durvalumab), a CTLA4 inhibitor (e.g., an anti-CTLA4 antibody), a LAG3 inhibitor (e.g., an anti-LAG3 antibody), a TIM3 inhibitor (e.g., an anti-TIM3 antibody), or a CD96 inhibitor (e.g., an anti-CD96 antibody).

~~37. The method or composition of Claim 30, wherein the immune checkpoint inhibitor is or comprises an anti-PD1 antibody.~~

~~38. The method or composition of Claim 31, wherein the anti-PD1 antibody is selected from Pembrolizumab, Nivolumab, or Cemiplimab.~~

~~39. he method or composition of Claim 30, wherein the immune checkpoint inhibitor is or comprises an anti-PD-L1 antibody.~~

~~40. The method or composition of Claim 33, wherein the anti-PD1 antibody is selected from Atezolizumab, Avelumab, or Durvalumab.~~

~~41.~~18. The ~~method, combination,~~use or composition of any one of c~~C~~laims ~~26 to 29~~14-17, wherein the MAPK pathway inhibitor is or comprises a MEK1/2 inhibitor.

~~42.~~19. The ~~method~~ use or composition of claim ~~35~~18, wherein the MEK1/2 inhibitor is selected from selumetanib and/or trematinib.

~~43. The method or composition of any one of Claims 26 to 29, wherein the BET inhibitor is JQ1.~~

~~44.~~20. The ~~method~~ use of any one of c~~C~~laims ~~26~~ 14 and ~~28 to 37~~16-19, wherein the population of allogeneic T cells is administered prior to, simultaneously with and/or subsequent to administration of the therapeutic agent, optionally further including the initial step of generating the population of allogeneic T cells *in vitro*.

~~45. The method of any one of Claims 26 and 28 to 38, further including the initial step of generating the population of allogeneic T cells *in vitro*.~~

~~46. The method or composition of any one of claims 26 to 39, wherein the EBV antigen and/or the further EBV antigen is selected from the group consisting of EBNA1, EBNA2, EBNA3A, EBNA3B, EBNA3C, LMP1, LMP2 and any combination thereof.~~

~~47. The method or composition of Claim 40, wherein the EBV antigen and/or the further EBV antigen is or comprises EBNA1, LMP1 and/or LMP2.~~

~~48. The method or composition of any one of Claims 26 to 41, wherein the cancer or tumour is selected from the group consisting of nasopharyngeal carcinoma, NKT cell lymphoma, Hodgkin's Lymphoma, post-transplant lymphoproliferative disease, Burkitt's lymphoma, Diffuse large B-cell lymphoma, gastric cancer, and any combination thereof.~~